Trial Profile
Phase 1 / 2 Trial of Idasanutlin in Combination With Ixazomib and Dexamethasone in Patients With 17p Deleted, Relapsed Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Idasanutlin (Primary) ; Ixazomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 21 Sep 2023 Planned End Date changed from 1 Dec 2023 to 31 Dec 2024.
- 03 Jul 2023 Planned End Date changed from 13 May 2023 to 1 Dec 2023.
- 01 Jun 2022 Planned End Date changed from 13 May 2022 to 13 May 2023.